Pharmaceutical

EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC

EMA's CHMP has recommended the approval of CStone's sugemalimab for the first-line treatment of metastatic non-small cell lung cancer.

Jun 4, 2024 - 04:00
EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC
EMA's CHMP has recommended the approval of CStone's sugemalimab for the first-line treatment of metastatic non-small cell lung cancer.
Read the original article

Tags:

Previous Article

Inline, real-time PAT tool is a game-changer for pharma granulation sector

Next Article

FDA approves Moderna’s RSV vaccine mRESVIA

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: European regulatory panel weighs against approval of Mirati’s KRAS-targeted lung cancer drug

STAT+: European regulatory panel weighs against approva...

Jul 22, 2023

STAT+: Pharmalittle: We’re reading about opioid settlements, an OTC birth control pill, and more

STAT+: Pharmalittle: We’re reading about opioid settlem...

Feb 3, 2024

UK’s NICE recommends AstraZeneca’s olaparib to treat cancer types

UK’s NICE recommends AstraZeneca’s olaparib to treat ca...

Apr 8, 2023